Keycute

Human Normal Immunoglobulin, the active ingredient in Keycute, is a immunoglobulin presented as a solution for subcutaneous injection for subcutaneous use. The product is derived from pooled plasma collected in the European Union and undergoes rigorous viral inactivation and purification processes to ensure safety and consistency. It treats primary immunodeficiency diseases in patients with deficient antibody production.

GNH USA supplies Keycute as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, providing reliable cold‑chain logistics and regulatory support for global distribution.

Keycute, a human normal immunoglobulin, is used in the management of primary immunodeficiency diseases by providing passive immunity.

Primary immunodeficiency diseases: restores IgG levels to reduce infection frequency and severity. Common variable immunodeficiency: improves antibody response and decreases need for antibiotics. X‑linked agammaglobulinemia: supplies missing IgG to protect against bacterial infections.

Keycute may be associated with a range of adverse reactions following subcutaneous administration.

Common Side Effects: - Injection site pain or erythema - Headache - Fatigue - Nausea

Serious or Rare Side Effects: - Anaphylaxis or severe allergic reaction - Thromboembolic events (deep vein thrombosis, pulmonary embolism) - Renal dysfunction or acute kidney injury - Aseptic meningitis

Keycute requires careful clinical monitoring to ensure safe use.

Dose adjustment: individualize based on IgG trough levels and clinical response. Renal function: monitor in patients with pre‑existing kidney disease. Thrombotic risk: assess history of clotting disorders before therapy. Infection risk: remain vigilant for viral transmission despite donor screening. Pregnancy and lactation: use only if benefit outweighs potential risk, as category is unknown. Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Keycute may interact with several medicines and vaccines.

Major Interactions (Avoid): - Live vaccines: may cause uncontrolled infection. - Immunosuppressants (e.g., rituximab): may reduce efficacy of immunoglobulin. - High‑dose aspirin or anticoagulants: increase bleeding risk at injection sites. - Cytotoxic chemotherapy: may exacerbate immunosuppression.

Moderate Interactions (Monitor Closely): - ACE inhibitors: monitor for angioedema. - Diuretics: monitor renal function during therapy. - Inactivated vaccines: may have reduced immunogenic response.